Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
HPV Infections
BIOLOGICAL: Cervarix|BIOLOGICAL: Gardasil
Measurable antibody mediated neutralisation of HPV serotype 6, 11, 16, 18 and genetically related serotypes, especially 45, 18 months from enrollment
Determine differences in vaccine formulation and their impact on cross protection., 24 months from enrollment
This study looks at possible cross reactivity between different HPV serotypes and both peripheral antibodies and mucosally-secreted antibodies.